Skip to main content

Advertisement

Table 6 Disaggregated base case results including cost components and incremental results

From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

Conventional care failure population
  Cost components (€)
Drug costs (€) Administration costs Health state costs Indirect costs Adverse event cost
Ustekinumab 50,352 312 55,127 111,987 14,447
Adalimumab 41,942 996 57,767 118,962 19,543
  1. QALY quality adjusted life year, ICER incremental cost-effectiveness ratio, TNF tumour necrosis factor
  Total and incremental results
Cost (€) Incremental cost QALYs Incremental QALYs ICER (€)
Ustekinumab 232,225   14.275   
Adalimumab 239,209 6984 14.043 − 0.232 Dominated
  1. QALY quality adjusted life year, ICER incremental cost-effectiveness ratio, TNF tumour necrosis factor
TNF-alpha failure population
  Cost components (€)
Drug costs (€) Administration costs Health state costs Indirect costs Adverse event cost
Vedolizumab 31,885 2293 62,767 132,895 14,881
Ustekinumab 43,501 336 61,206 128,843 14,859
  1. QALY quality adjusted life year, ICER incremental cost-effectiveness ratio, TNF tumour necrosis factor
  Total and incremental results
Total cost (€) Incremental cost Total QALYs Incremental QALYs ICER (€)
Vedolizumab 244,721   14.047   
Ustekinumab 248,745 4023 14.180 0.133 30,282
  1. QALY quality adjusted life year, ICER incremental cost-effectiveness ratio, TNF tumour necrosis factor